[go: up one dir, main page]

WO2002028853A1 - Benzylamine compound, process for producing the same, and intermediate therefor - Google Patents

Benzylamine compound, process for producing the same, and intermediate therefor Download PDF

Info

Publication number
WO2002028853A1
WO2002028853A1 PCT/JP2001/008616 JP0108616W WO0228853A1 WO 2002028853 A1 WO2002028853 A1 WO 2002028853A1 JP 0108616 W JP0108616 W JP 0108616W WO 0228853 A1 WO0228853 A1 WO 0228853A1
Authority
WO
WIPO (PCT)
Prior art keywords
producing
benzylamine compound
same
halogeno
intermediate therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/008616
Other languages
French (fr)
Japanese (ja)
Inventor
Masami Takahashi
Masakatsu Sugahara
Hiroshi Mizuuchi
Akira Saito
Taketoshi Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Priority to AU2001292320A priority Critical patent/AU2001292320A1/en
Publication of WO2002028853A1 publication Critical patent/WO2002028853A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pyridine Compounds (AREA)

Abstract

A benzylamine compound represented by the general formula (I) or a pharmacologically acceptable salt thereof: (I) wherein R1 represents a fused aromatic heterocyclic group which has one to four heteroatoms selected among nitrogen, oxygen, and sulfur atoms and has been optionally substituted by halogeno, oxo, nitro, cyano, lower alkyl, lower halogenoalkyl, lower alkoxy, pyridyl, etc.; and R?2 and R3¿ each represents hydrogen, halogeno, lower alkyl, lower halogenoalkyl, or lower alkoxy.
PCT/JP2001/008616 2000-10-02 2001-10-01 Benzylamine compound, process for producing the same, and intermediate therefor Ceased WO2002028853A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292320A AU2001292320A1 (en) 2000-10-02 2001-10-01 Benzylamine compound, process for producing the same, and intermediate therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000301563 2000-10-02
JP2000-301563 2000-10-02

Publications (1)

Publication Number Publication Date
WO2002028853A1 true WO2002028853A1 (en) 2002-04-11

Family

ID=18783085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008616 Ceased WO2002028853A1 (en) 2000-10-02 2001-10-01 Benzylamine compound, process for producing the same, and intermediate therefor

Country Status (2)

Country Link
AU (1) AU2001292320A1 (en)
WO (1) WO2002028853A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030695A1 (en) * 2002-10-04 2004-04-15 The University Of Reading Treatment of vascular diseases
WO2005016862A1 (en) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
WO2005034869A3 (en) * 2003-10-08 2005-07-07 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US7645764B2 (en) 2006-11-09 2010-01-12 Roche Palo Alto Llc Kinase inhibitors and methods for using the same
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
JP2012533541A (en) * 2009-07-15 2012-12-27 インテリカイン， エルエルシー Specific chemicals, compositions and methods
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
AU2011265521B2 (en) * 2005-07-15 2013-10-31 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
WO1992017449A1 (en) * 1991-03-26 1992-10-15 Pfizer Inc. Stereoselective preparation of substituted piperidines
WO1994004496A1 (en) * 1992-08-19 1994-03-03 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
WO1994013663A1 (en) * 1992-12-10 1994-06-23 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
WO1995008549A1 (en) * 1993-09-22 1995-03-30 Glaxo Group Limited 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
WO1997001554A1 (en) * 1995-06-28 1997-01-16 Merck Sharp & Dohme Limited Piperidine and morpholine derivatives and their use as therapeutic agents
WO1997021702A1 (en) * 1995-12-11 1997-06-19 Merck Sharp & Dohme Limited 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
WO1992017449A1 (en) * 1991-03-26 1992-10-15 Pfizer Inc. Stereoselective preparation of substituted piperidines
WO1994004496A1 (en) * 1992-08-19 1994-03-03 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
WO1994013663A1 (en) * 1992-12-10 1994-06-23 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
WO1995008549A1 (en) * 1993-09-22 1995-03-30 Glaxo Group Limited 3-(5-tetrazolyl-benzyl)amino-piperidine derivatives and antagonists of tachykinins
WO1997001554A1 (en) * 1995-06-28 1997-01-16 Merck Sharp & Dohme Limited Piperidine and morpholine derivatives and their use as therapeutic agents
WO1997021702A1 (en) * 1995-12-11 1997-06-19 Merck Sharp & Dohme Limited 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARBONNELLE A.C. ET AL., TETRAHEDRON LETT., vol. 39, no. 25, 1998, pages 4467 - 4470, XP002912910 *
CHEMICAL ABSTRACTS, vol. 51, Columbus, Ohio, US; abstract no. 8081F-8082C, XP002906375 *
SCI. PROC. ROY. DUBLIN SOC., vol. 27, 1956, pages 111 - 117 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030695A1 (en) * 2002-10-04 2004-04-15 The University Of Reading Treatment of vascular diseases
US7470807B2 (en) 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
JP2007528362A (en) * 2003-08-14 2007-10-11 旭化成ファーマ株式会社 Substituted arylalkanoic acid derivatives and uses thereof
WO2005016862A1 (en) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
JP4758349B2 (en) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005034869A3 (en) * 2003-10-08 2005-07-07 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007508310A (en) * 2003-10-08 2007-04-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
US7449582B2 (en) 2003-10-08 2008-11-11 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2011265521B2 (en) * 2005-07-15 2013-10-31 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9051267B2 (en) 2005-11-28 2015-06-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US7678792B2 (en) 2006-10-20 2010-03-16 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US8106068B2 (en) 2006-10-20 2012-01-31 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US7645764B2 (en) 2006-11-09 2010-01-12 Roche Palo Alto Llc Kinase inhibitors and methods for using the same
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
JP2012533541A (en) * 2009-07-15 2012-12-27 インテリカイン， エルエルシー Specific chemicals, compositions and methods
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
AU2001292320A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
WO2002028853A1 (en) Benzylamine compound, process for producing the same, and intermediate therefor
WO2002024650A3 (en) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
AU3053999A (en) Nitrogenous heterocyclic compounds
TW200738629A (en) Ethylenediamine derivatives
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
WO2002044153A8 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
EP1479684A4 (en) THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
EP1184373A4 (en) Tricyclic compounds
WO2005105096A3 (en) Fused heterocyclic compounds
EP1640366A4 (en) Heterocyclic methyl sulfone derivative
BG104447A (en) Biphenylamidine derivatives
EP1043312A4 (en) Heterocyclic compounds having nos inhibitory activities
CA2273303A1 (en) Thienylsulfonylamino(thio)carbonyl compounds
EP1741714A4 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
HUT75649A (en) Optically active imidazolidinone derivative and pharmaceutical compositions containing them
EP1043311A4 (en) Biphenylamidine derivatives
DK1338596T3 (en) Process for Preparation of Carbapenem Antibacterial Agent
EP1099690A4 (en) Monocyclic beta-lactam compounds and chymase inhibitors containing the same
YU64699A (en) Quaternary ammonium compounds as tachykinin antagonists
WO2001010861A3 (en) Substituted heterocyclyl-2h-chromenes
ATE375343T1 (en) NEW BETA-LACTAM COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
AU3648093A (en) Pyrrolidine derivatives useful as 5-HT3-antagonists
WO2003004464A8 (en) Heterocyclic amide derivatives and the use thereof as pesticides
AP2001002314A0 (en) Substituted benzolactam compounds.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS KR LC LK LR LT LV MA MG MK MN MX NO NZ PH PL RO SG SI SK TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase